35 years old \<age≤55 years old, in premenopausal status(with the judgement by researchers when the patients are recruited) Histologically confirmed primary invasive breast cancer
Stage: T2N0M0(cT\>2cm, SLNB negative), hard to proceed the breast conserving surgery(not feasible or may affect the appearance of breast)
Histologically confirmed HR+ (ER or PR positive, and \>50% cell in IHC) HER2 negative breast cancer by pathological evaluation
No other previous treatment for primary breast cancer
Without other tumor or unstable complication or uncontrolled infection
No contradiction for the third generation AIs, LHRHa, chemotherapy
Attend the study voluntarily, sign the informed consent.
You may not be if
Metastasis disease by pathological or radiological diagnosis
the history of other tumor
contradiction for the third generation AIs, LHRHa, chemotherapy
Contradiction for adjuvant chemotherapy: serious cardiology or cerebral vessel disease, liver or kidney disfunction, blood system disease, the other situation or complication that are not suitable or cannot adaptable for chemotherapy
Contradiction for proceeding surgery: contradiction for anesthesia, large lesion,T4, lymph node positive
other situation not suitable for the research: psychological disease, mental disorder, social problem, geographic problem
have been attendance in other anti-tumor treatment or other clinical trials 8) reject to attend the study
Clareo Health | Neoadjuvant Endocrine Therapy Versus Chemotherapy in Premenopausal Patients With ER+ & HER2- Breast Cancer
